Regulatory Strategy Services

Low data variability

Our core ECG laboratory provides a centralised system for all our studies. High precision ECG acquisition in our clinic provides meaningful ECG analysis with a smaller sample size, making us the ideal choice for the integration of cardiac safety in FIH and MAD studies.

We are a leading publisher in cardiology and have publicly accessible credentials. We are proud of our integrity, our professional growth and experience in this field.

Learn more about our ECG Lab

Exceptional ECG generation

We undertake and analyse several cardiological assessments using state-of-the-art equipment to understand and explain abnormal ECG data obtained during a clinical study of a new chemical entity.

Learn more about our cardio analysis services

Experts in cardiac safety

Richmond Pharmacology’s Core ECG Laboratory team are based within St George’s Hospital Medical School, London and are made up of highly experienced cardiologists headed by Professor John Camm, a key opinion leader in TQT Trials.

Learn more about our expert cardiologists

Our Services

MHRA Clinical Trial Application Derisking

Strategic review of documents (e.g. IBs, CSPs, GNAs), REC preparation, and global alignment

Scientific Advice Support

End-to-end support for MHRA interactions—briefing book writing, question development, and mock meetings

Accelerated Pathways (e.g., ILAP)

Strategy development, workshop delivery, document authoring, and submission

Paediatric Investigation Plans (PIPs)

Regulatory intelligence, strategy, and submission (incl. waivers, deferrals, and PDCO responses)

Regulatory Roadmaps

Tailored plans from discovery through post-marketing, aligned with your product type, timeline, and markets

Cross-Functional Integration

Support that bridges clinical, regulatory, CMC, and commercial teams

Get in touch

Meet Lisa Campbell

Lisa Campbell leads Richmond Pharmacology’s Regulatory Strategy and Medical Writing teams. With over 20 years of experience spanning regulatory science, clinical medicine, and drug development, Lisa offers unique insight and practical strategy.

Previously a Senior Medical Assessor at the MHRA, Lisa contributed to the development of the Innovative Licensing and Access Pathway (ILAP) and assessed complex trial designs including adaptive and first-in-human studies. She has advised on global clinical programmes for gene therapies, rare diseases, and emerging technologies.

Lisa is an expert in regulatory compliance, trial design, and public policy. She is published in Nature Medicine, BMJ Open, and JAMA. Her areas of interest include Patient-Focused Drug Development and the integration of patient perspectives into clinical research and regulatory strategy.

At Richmond, Lisa ensures that clients receive intelligent, compliant, and patient-centred regulatory guidance, accelerating access to innovative therapies.

Contact us today to discuss how we can support your clinical development with expert, compliant, and forward-thinking regulatory solutions.

Meet the experts

Richmond Pharmacology has a team of experts with extensive knowledge of clinical research trials.

Careers at Richmond

We are on the lookout for people who love what they do, strive for excellence and who want to make a difference.

Our Videos

Learn more about Richmond Pharmacology by viewing some of our videos.

Latest news

Richmond Pharmacology Welcomes Back Dr Edward Jackson as Medical Director

November 3, 2025

Richmond Pharmacology is pleased to announce the return of Dr Edward Jackson, who re-joins the organisation as Medical Director.

JSCPT 2025

5 – 6 December 2025

Richmond Pharmacology will attend JSCPT 2025 in Tokyo, represented by their leadership team. Topics include early-phase studies, bridging studies between Europe and Asia, gene and RNA-based therapy development, and cross-border collaboration.

View event

Our specialist services